Published online before print December 8, 2003, doi: 10.1161/01.CIR.0000105763.51286.7F
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:178-183.)
© 2004 American Heart Association, Inc.
Clinical Investigation and Reports |
Inhibition of Cytochrome P450 2C9 Improves Endothelium-Dependent, Nitric Oxide–Mediated Vasodilatation in Patients With Coronary Artery Disease
From the Departments of Internal Medicine IV, Division of Cardiology (S.F., S.D., S.B., A.M.Z.) and Cardiovascular Physiology (R.B., I.F.), Johann W. Goethe-University, Frankfurt am Main, Germany.
Correspondence to Ingrid Fleming, PhD, Institut für Kardiovaskuläre Physiologie, Johann W. Goethe University, Theodor Stern Kai 7, D-60590 Frankfurt, Germany. E-mail fleming{at}em.uni-frankfurt.de
Received March 6, 2003; de novo received June 17, 2003; revision received September 12, 2003; accepted September 18, 2003.
Background— Nitric oxide (NO)– and prostacyclin-independent vasodilatation in several vascular beds has been linked to the activation of cytochrome P450 (CYP) epoxygenases expressed in endothelial cells. However, these enzymes, which generate vasodilator epoxyeicosatrienoic acids, may also produce oxygen-derived free radicals, which attenuate the bioavailability of NO. Here, we studied the involvement of CYP 2C9 in modulating endothelium-dependent and -independent changes in forearm blood flow (FBF) in healthy volunteers and in patients with manifest coronary artery disease.
Methods and Results— The effects of sulfaphenazole, a selective inhibitor of CYP 2C9, on endothelium-dependent (acetylcholine) and endothelium-independent (sodium nitroprusside, SNP) FBF responses were measured by venous occlusion plethysmography in 5 healthy subjects and in 16 patients with angiographically documented stable coronary artery disease. Sulfaphenazole did not modify FBF responses to acetylcholine or SNP in healthy subjects. In contrast, sulfaphenazole markedly and dose-dependently enhanced the FBF response to acetylcholine without affecting the response to SNP. Vitamin C also increased the FBF response to acetylcholine, but this effect was further potentiated by sulfaphenazole. In the presence of N
-monomethyl-L-arginine, sulfaphenazole failed to significantly improve acetylcholine-induced vasodilatation. The oxidation of serum proteins was enhanced in patients with coronary artery disease, and this effect was significantly attenuated by sulfaphenazole.
Conclusions— The CYP 2C9 inhibitor sulfaphenazole enhances endothelium-dependent vasodilator responses in patients with manifest coronary artery disease. This effect seems to be related to an increase in the bioavailability of NO, probably as a consequence of an attenuated generation of reactive oxygen species by CYP 2C9 in endothelial cells.
Key Words: blood flow • coronary artery disease • endothelium-derived factors • free radicals • nitric oxide
This article has been cited by other articles:
 |
|
 |
|
  A. J. Donato, I. Eskurza, K. L. Jablonski, L. B. Gano, G. L. Pierce, and D. R. Seals Cytochrome P-450 2C9 signaling does not contribute to age-associated vascular endothelial dysfunction in humans J Appl Physiol, October 1, 2008; 105(4): 1359 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lorenzo and C. T. Minson Human cutaneous reactive hyperaemia: role of BKCa channels and sensory nerves J. Physiol., November 15, 2007; 585(1): 295 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Ingram, S. C. Newcomer, E. M. Price, K. E. Eklund, R. M. McAllister, and M. H. Laughlin Chronic nitric oxide synthase inhibition blunts endothelium-dependent function of conduit coronary arteries, not arterioles Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2798 - H2808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bellien, M. Iacob, L. Gutierrez, M. Isabelle, A. Lahary, C. Thuillez, and R. Joannides Crucial Role of NO and Endothelium-Derived Hyperpolarizing Factor in Human Sustained Conduit Artery Flow-Mediated Dilatation Hypertension, December 1, 2006; 48(6): 1088 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Quyyumi and M. Ozkor Vasodilation by Hyperpolarization: Beyond NO Hypertension, December 1, 2006; 48(6): 1023 - 1025. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Taddei, D. Versari, A. Cipriano, L. Ghiadoni, F. Galetta, F. Franzoni, A. Magagna, A. Virdis, and A. Salvetti Identification of a Cytochrome P450 2C9-Derived Endothelium-Derived Hyperpolarizing Factor in Essential Hypertensive Patients J. Am. Coll. Cardiol., August 1, 2006; 48(3): 508 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Feletou and P. M. Vanhoutte Endothelium-Derived Hyperpolarizing Factor: Where Are We Now? Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1215 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bellien, R. Joannides, M. Iacob, P. Arnaud, and C. Thuillez Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1347 - H1352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Fleming and R. Busse Endothelium-Derived Epoxyeicosatrienoic Acids and Vascular Function Hypertension, April 1, 2006; 47(4): 629 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pokreisz, I. Fleming, L. Kiss, E. Barbosa-Sicard, B. Fisslthaler, J. R. Falck, B. D. Hammock, I.-H. Kim, Z. Szelid, P. Vermeersch, et al. Cytochrome P450 Epoxygenase Gene Function in Hypoxic Pulmonary Vasoconstriction and Pulmonary Vascular Remodeling Hypertension, April 1, 2006; 47(4): 762 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Gross, J. R. Falck, E. R. Gross, M. Isbell, J. Moore, and K. Nithipatikom Cytochrome P450 and arachidonic acid metabolites: Role in myocardial ischemia/reperfusion injury revisited Cardiovasc Res, October 1, 2005; 68(1): 18 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Imig Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases Am J Physiol Renal Physiol, September 1, 2005; 289(3): F496 - F503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Schrage, N. M. Dietz, J. H. Eisenach, and M. J. Joyner Agonist-dependent variablity of contributions of nitric oxide and prostaglandins in human skeletal muscle J Appl Physiol, April 1, 2005; 98(4): 1251 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Fleming Cytochrome P-450 Under Pressure: More Evidence for a Link Between 20-Hydroxyeicosatetraenoic Acid and Hypertension Circulation, January 4, 2005; 111(1): 5 - 7. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Funk, G. Endler, R. Freitag, J. Wojta, K. Huber, C. Mannhalter, and R. Sunder-Plassmann CYP2C9*2 and CYP2C9*3 Alleles Confer a Lower Risk for Myocardial Infarction Clin. Chem., December 1, 2004; 50(12): 2395 - 2398. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Li and A. M Shah Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1014 - R1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Traupe and M. Barton Protease-activated receptors and EDHF: the icing on the cake? Cardiovasc Res, March 1, 2004; 61(4): 645 - 647. [Full Text] [PDF]
|
|